DGAT-2 inhibitor - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

US-Canada trade tensions intensified after last-minute negotiations collapsed, triggering 50% US tariffs on roughly C$28 billion of Canadian goods and a pledge of equivalent retaliation from Prime Minister Mark Carney. Representative image.

US-Canada trade deal falls apart at the deadline as 50% tariffs revive economic confrontation

Three-year Bar rule reduced as Supreme Court creates new Civil Judge recruitment pathway

Telangana pharma factory explosion kills two workers and leaves two critically burned

Alvotech (Nasdaq: ALVO) lands $150m Lotus biosimilar deal across US, Asia

Read More

Pharma Industry News

Madrigal Pharmaceuticals adds Phase 2 DGAT-2 inhibitor ervogastat to MASH pipeline under global licensing agreement

Find out how Madrigal Pharmaceuticals is expanding its MASH strategy with a global license for ervogastat, a Phase 2 DGAT-2 inhibitor.

bySoujanya Ravi

January 12, 2026

web analytics